The newly emerging human pathogen influenza A H7N9 represents a potentially major threat to human health. The virus was first shown to be pathogenic in humans in 2013, and outbreaks continue to occur in China to the present time. The current incident mortality rate is disturbingly high despite the frequent use of antiviral therapy and intensive care management. If the virus gains the capacity for efficient person-to-person transmission, a global influenza pandemic could ensue with devastating consequences. In the absence of an effective vaccine, targeted regulation of the host immune response by immune modulators might be considered. Readily available, approved drugs with immune-modulating activities might prove to be a treatment option in combination with existing antiviral agents and supportive care. © 2014 Opal and Fedson; licensee BioMed Central Ltd.
Opal, S. M., & Fedson, D. S. (2014, April 22). The dysfunctional host response to influenza A H7N9: A potential treatment option? Critical Care. BioMed Central Ltd. https://doi.org/10.1186/cc13839